NCT02642614 - Safety, Tolerability and Pharmacokinetics and Effect on Inflammation of Oral BI 1026706 in Patients With COPD | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

January 25, 2016

Primary Completion Date

June 14, 2016

Study Completion Date

June 14, 2016

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

BI 1026706

DRUG

Placebo

DRUG

Placebo

For blinding purposes

Trial Locations (10)

Bispebjerg og Frederiksberg Hospital, København NV

Odense University Hospital, Odense C

PAREXEL International GmbH, Berlin

Pneumologisches Forschungsinstitut an der LungenClinic Grosshansdorf GmbH, Großhansdorf

KLB Gesundheitsforschung Lübeck GmbH, Lübeck

Fraunhofer ITEM, Hanover

IKF Pneumologie GmbH & Co. KG, Frankfurt

Inamed GmbH, Gauting

Skånes universitetssjukhus, Lund, Lund

The Medicines Evaluation Unit, Manchester